September 7, 2017, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO) (OTCQB: ICOTF), today announced that it has been invited to present at the following upcoming conferences:

19th Annual Rodman and Renshaw Global Investment Conference, New York, New York

iCo is currently scheduled to present at the 19th Annual Rodman and Renshaw Global Investment Conference being held between September 10th and 12th, 2017 at the Lotte New York Palace Hotel, New York, New York. Management will provide an investor update on Tuesday September 12, 2017 at 4:15 PM ET in the Holmes II hotel meeting room. For more information please see: http://www.meetmax.com/sched/event_39839/~public/conference_home.html?event_id=39839

Boston Biotech Anti-Infectives Rx Conference, Boston, Massachusetts

iCo is currently scheduled to present at the Boston Biotech Anti-Infectives Rx Conference being held on September 19th, 2017 at the Harvard Medical School Joseph B. Martin Conference Center, Boston, Massachusetts. Management will participate in a panel discussion at September 19th, 2017 at 10:30 AM ET. For additional information please see:http://bbbiotechconference.com/conference-details.php?id=61

Additionally, Management will be attending the 10th Annual BioPharm America International Partnering Conference being held between September 26th and 27th, 2017 at the Sheraton Boston Hotel, Boston, Massachusetts. For more information refer to:
https://ebdgroup.knect365.com/biopharm-america/

About iCo Therapeutics

iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus areas and if so the Company will seek to capture further value via partnerships, such as its partnership with Immune Pharmaceuticals (NASDAQ: IMNP), which is in several Phase 2 studies involving iCo-008. iCo

shares trade on the TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”. For more information, visit the Company website at: icotherapeutics.cdmail.biz.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking statements” within the meaning of applicable

securities laws. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Andrew Rae, CEO 778-772-7775 rae@icotherapeutics.cdmail.biz